Table 1 Baseline characteristics of the patients
Characteristic | Placebo | WJMSCs | P value |
|---|---|---|---|
(n = 58) | (n = 58) | ||
Risk factor | |||
Age (years) | 56.7±1.7 | 57.3±1.3 | 0.79 |
Men - number (%) | 51(87.9) | 55(94.8) | 0.18 |
Body-mass index (kg/m2) | 25.4±0.3 | 24.9±0.3 | 0.26 |
Diabetes mellitus - number (%) | 14(24.1) | 17(29.3) | 0.52 |
Hyperlipidemia - number (%) | 22(37.9) | 21(36.2) | 0.84 |
Hypertension - number (%) | 26(44.8) | 33(56.9) | 0.19 |
Smoking (current of former) -number (%) | 32(55.2) | 34(58.6) | 0.70 |
Family history of coronary heart disease - number (%) | 20(34.5) | 17(29.3) | 0.55 |
Coronary artery disease - number (%) | 0.19 | ||
1-Vessel disease | 28(48.3) | 21(36.2) | |
2-Vessel disease | 16(27.6) | 14(24.1) | |
3-Vessel disease | 14(24.1) | 23(39.7) | |
Infarct treatment | |||
Infarct-related artery - number (%) | 0.55 | ||
Left anterior descending artery | 31(53.4) | 29(50.0) | |
Left circumflex artery | 6(10.3) | 10(17.2) | |
Right coronary artery | 21(36.2) | 19(32.8) | |
PCI for additional stenoses in non-infarct-related vessels - number (%) | 10(17.2) | 15(25.9) | 0.25 |
Time from symptom onset to first reperfusion therapy-hour | |||
Mean | 7.3±0.5 | 7.2±0.5 | 0.81 |
Median | 6.3 | 7.3 | |
Drug-eluting stent - number (%) | 58(100) | 58(100) | 1 |
Gp II b/IIIa inhibitor during acute PCI - number (%) | 7(12.1) | 8(13.8) | 0.78 |
Intravenous catecholamines - number (%) | 3(5.2) | 4(6.9) | 0.69 |
Maximal creatine kinase (U/L) | 1899±273 | 1653±206 | 0.93 |
Maximal creatine kinase MB (U/L) | 192±21 | 170±17 | 0.42 |
Maximal troponin T (μg/L) | 18.2±3.1 | 24.7±4.1 | 0.61 |
TIMI flow grade | |||
Before PCI - number (%) | 0.93 | ||
Grade 0 or 1 | 42(72.4) | 42(72.4) | |
Grade 2 | 8(13.8) | 7(12.1) | |
Grade 3 | 8(13.8) | 9(15.5) | |
After PCI - number (%) | 0.55 | ||
Grade 0 or 1 | 0(0) | 0(0) | |
Grade 2 | 1(1.7) | 2(3.4) | |
Grade 3 | 57(98.3) | 56(96.6) | |
Baseline quantitative measure of LV function | |||
Global left ventricular ejection fraction (%) | |||
Mean | 51.1±1.0 | 52.0±0.9 | 0.51 |
Left venticular fractional shortening (%) | |||
Mean | 26.4±0.6 | 27.2±0.6 | 0.33 |
Wall motion score index (17-segment model) | |||
Mean | 1.28±0.03 | 1.29±0.02 | 0.62 |
End-systolic volume (ml) | |||
Mean | 64.6±2.8 | 63.3±2.7 | 0.68 |
End-diastolic volume (ml) | |||
Mean | 129.9±3.5 | 130.4±3.6 | 0.90 |
Cell therapy | |||
Time from reperfusion to infusion of study therapy-days | |||
Mean | 6.3±0.1 | 6.1±0.1 | 0.25 |
Median | 6.5 | 6.0 | |
TIMI flow grade before study therapy | |||
Mean | 2.98±0.02 | 2.97±0.02 | 0.56 |
Median | 3 | 3 | |
TIMI flow grade after study therapy | |||
Mean | 2.98±0.02 | 2.97±0.02 | 0.56 |
Median | 3 | 3 | |
Current medication - number (%) | |||
Aspirin and clopidogrel | 58(100) | 58(100) | 1 |
Beta-blocker | 48(82.8) | 42(72.4) | 0.18 |
ACE-inhibitors or angiotensin-receptor B | 43(74.1) | 42(72.4) | 0.83 |
Stains | 54(93.1) | 54(93.1) | 1 |